Big Health, a leading developer of digital treatments for the most pervasive mental health conditions, today announced a new round of strategic funding of $23.7 million to accelerate access to its FDA-cleared, reimbursable solutions (SleepioRx for insomnia disorder and DaylightRx for generalized anxiety disorder (GAD)).

Big Health's mission is to help millions improve their mental health by providing safe and effective digital treatments for the most common mental health conditions, including insomnia and anxiety. Designed by leading clinical experts, Big Health's digital mental health treatments expand access to gold'standard care, including behavioral medicine, and are backed by industry'leading research and randomized controlled trials. By making treatments available both directly to patients and through providers, and by simplifying adoption for providers, payers, and employers, Big Health is increasing access to affordable evidence-based care.